Pharmacy benefit manager reforms through regulatory and legislative actions are weaker than promised. Furthermore, PBMs will likely adapt by finding new revenue streams.

Independent, peer-reviewed data, rather than a press release alone, remain essential for a complete and accurate understanding of a product’s efficacy and safety.

New trial results indicate that the targeted cancer drug Daraxonrasib might also be beneficial for some patients with lung cancer.

New trial results indicate that the targeted cancer drug Daraxonrasib might also be beneficial for some patients with lung cancer.

Thinking about the future, it’s inevitable that other cancer drugs like Rasonque will launch at similar or even higher prices. In the long run, how sustainable is this?

Since USPSTF recommendations guide insurer decisions on what types of preventive care to fully cover, the panel’s ongoing upheaval may lead to coverage limits.

A new molecular glue reprograms the lymphoma protein BCL6 to switch cancer-cell death back on, clearing aggressive tumors in mice in just 11 days.

The Trump administration has mostly shut down the Agency for Healthcare Research and Quality, which has been key in raising awareness and improving patient safety.

Bank of America is bucking the downward trend in employer-sponsored coverage of GLP-1s for weight loss by maintaining its comparatively generous policies.

President Trump vowed better access to GLP-1 weight loss drugs for Medicaid recipients. But thus far only Indiana has publicly signed on with the administration’s demo.